JP2022540946A5 - - Google Patents

Info

Publication number
JP2022540946A5
JP2022540946A5 JP2022503470A JP2022503470A JP2022540946A5 JP 2022540946 A5 JP2022540946 A5 JP 2022540946A5 JP 2022503470 A JP2022503470 A JP 2022503470A JP 2022503470 A JP2022503470 A JP 2022503470A JP 2022540946 A5 JP2022540946 A5 JP 2022540946A5
Authority
JP
Japan
Application number
JP2022503470A
Other languages
Japanese (ja)
Other versions
JP7455188B2 (ja
JP2022540946A (ja
JPWO2021013068A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2020/102585 external-priority patent/WO2021013068A1/en
Publication of JP2022540946A publication Critical patent/JP2022540946A/ja
Publication of JP2022540946A5 publication Critical patent/JP2022540946A5/ja
Publication of JPWO2021013068A5 publication Critical patent/JPWO2021013068A5/ja
Application granted granted Critical
Publication of JP7455188B2 publication Critical patent/JP7455188B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022503470A 2019-07-19 2020-07-17 コンジュゲーションのためのポリペプチド複合体及びその応用 Active JP7455188B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/096849 2019-07-19
CN2019096849 2019-07-19
PCT/CN2020/102585 WO2021013068A1 (en) 2019-07-19 2020-07-17 Polypeptide complex for conjugation and use thereof

Publications (4)

Publication Number Publication Date
JP2022540946A JP2022540946A (ja) 2022-09-20
JP2022540946A5 true JP2022540946A5 (https=) 2023-04-19
JPWO2021013068A5 JPWO2021013068A5 (https=) 2023-04-19
JP7455188B2 JP7455188B2 (ja) 2024-03-25

Family

ID=74193121

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022503470A Active JP7455188B2 (ja) 2019-07-19 2020-07-17 コンジュゲーションのためのポリペプチド複合体及びその応用

Country Status (9)

Country Link
US (1) US20220267467A1 (https=)
EP (1) EP3999544A4 (https=)
JP (1) JP7455188B2 (https=)
KR (1) KR102949500B1 (https=)
CN (1) CN114127117B (https=)
AU (1) AU2020318112C1 (https=)
CA (1) CA3147690A1 (https=)
TW (1) TWI845724B (https=)
WO (1) WO2021013068A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2022014698A1 (https=) * 2020-07-17 2022-01-20
CN118480117B (zh) * 2021-01-18 2025-03-04 上海药明合联生物技术有限公司 工程化抗体和包含工程化抗体的抗体-药物偶联物
CN116981695A (zh) * 2022-05-06 2023-10-31 上海药明合联生物技术有限公司 含工程化铰链区的抗体及其应用
TW202411249A (zh) * 2022-05-20 2024-03-16 大陸商上海邁晉生物醫藥科技有限公司 抗體-藥物偶聯物的製備方法
CN115947830B (zh) * 2022-12-27 2023-09-12 优洛生物(上海)有限公司 一种经改造的抗体、其制备方法及其用途
WO2026011391A1 (en) * 2024-07-11 2026-01-15 Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Anti-cd276 antibody, antibody-drug conjugate, and use thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103172731A (zh) * 2004-07-15 2013-06-26 赞科股份有限公司 优化的Fc变体
US7736647B2 (en) * 2005-06-15 2010-06-15 Monoclonal Antibodies Therapeutics Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells
MX2009012343A (es) * 2007-05-14 2010-02-10 Biogen Idec Inc Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello.
CA2777242A1 (en) * 2009-10-14 2011-04-21 Merrimack Pharmaceuticals, Inc. Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof
EP3511342B1 (en) * 2010-03-10 2024-01-17 Genmab A/S Monoclonal antibodies against c-met
WO2013096346A1 (en) * 2011-12-22 2013-06-27 Development Center For Biotechnology Bispecific t-cell activator antibody
KR101895634B1 (ko) * 2013-05-31 2018-09-05 한미약품 주식회사 변이된 힌지 영역을 포함하는 IgG4 Fc 단편
EP2871190A1 (en) * 2013-11-11 2015-05-13 ATLAB Pharma Antibody against GD2-O-acetylated ganglioside with pro-apoptotic activity
US10669328B2 (en) * 2013-11-12 2020-06-02 Ogd2 Pharma Human IgG1 derived antibody with pro-apoptotic activity
PL3212226T3 (pl) * 2014-10-31 2020-11-02 Ngm Biopharmaceuticals, Inc. Kompozycje i sposoby stosowania w leczeniu zaburzeń metabolicznych
WO2016156291A1 (en) * 2015-03-31 2016-10-06 F. Hoffmann-La Roche Ag Antigen binding molecules comprising a trimeric tnf family ligand
PT3294764T (pt) * 2015-05-15 2021-02-15 Hope City Composições de recetores de antigénios quiméricos
BR112018010172A2 (pt) * 2015-11-19 2018-11-21 Bristol Myers Squibb Co anticorpos contra receptor de fator de necrose de tumor induzido por glicocorticoide (gitr) e usos dos mesmos
CR20180453A (es) * 2016-03-22 2018-12-05 Hoffmann La Roche Moleculas biespecíficas de células t activadas por proteasas
GB201612520D0 (en) * 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
CN110177569A (zh) * 2017-03-30 2019-08-27 江苏恒瑞医药股份有限公司 抗体药物偶联物的制备方法
CN106892982B (zh) * 2017-04-05 2021-01-05 东北农业大学 靶向IL-17和TNFα的新型融合多肽及其应用
CN111032085A (zh) * 2017-06-05 2020-04-17 昆士兰医学研究所理事会 用于癌症治疗或预防的免疫检查点分子拮抗剂和rank-l(nf-kb配体)拮抗剂的组合或其双特异性结合分子及其用途
EP3634485A4 (en) * 2017-06-07 2021-07-21 Silverback Therapeutics, Inc. CONJUGATES OF ANTIBODIES CONTAINING IMMUNOMODULATOR COMPOUNDS AND THEIR USES
AU2018337142B2 (en) * 2017-09-22 2025-07-03 Wuxi Biologics Ireland Limited. Novel bispecific CD3/CD19 polypeptide complexes
CN109970860A (zh) * 2017-12-27 2019-07-05 信达生物制药(苏州)有限公司 三链抗体、其制备方法及其用途
CA3101019A1 (en) * 2018-06-01 2019-12-05 Compugen Ltd Anti-pvrig/anti-tigit bispecific antibodies and methods of use
CN109536450B (zh) * 2018-11-02 2021-02-19 北京贝来生物科技有限公司 一种阻断Th17信号通路治疗自身免疫病的间充质干细胞及其制备方法和应用
CN109628406B (zh) * 2019-01-03 2021-02-26 北京贝来生物科技有限公司 一种治疗自身免疫疾病的间充质干细胞及其制备方法和应用

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
JP2022540946A5 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR112023016292A2 (https=)
BR112023011610A2 (https=)
BR112023011539A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)
BR102021016375A2 (https=)